Compare MasterCard Inc (MA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Novo Nordisk A/S — how do they compare? MasterCard Inc trades at $573.15 (market cap $503.50B), while Novo Nordisk A/S trades at $38.25 (market cap $165.31B). The key difference: MasterCard Inc is far larger — about 3× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and Novo Nordisk A/S for 116 Days on average.
| MA | NVO | |
|---|---|---|
Market Cap | $503.50B | $165.31B |
Volume | 3,390,859 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $599.86 | $63.98 |
52-Week Low | $471.55 | $35.29 |
Typical Hold Time | 134 Days | 116 Days |
Enterprise Value | $516.53B | $179.56B |
Dividend Yield | 0.61% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $570.06, up 0.61% with strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to $32.79B in 2025 with impressive 46.34% net margins, though valuation multiples remain elevated with P/E at 31.61. Recent institutional buying activity and positive analyst coverage support the upward trend.
Mastercard presents a compelling growth story with expanding global payment volumes and digital transformation initiatives. The primary investment thesis centers on continued market share gains and margin expansion, though risks include payment industry disruption from stablecoins and elevated valuation multiples requiring sustained high growth. Analyst consensus targets $666.67 suggest 17% upside potential from current levels.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
